Leading U.S. Medical Association's Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations

Press/Media: Press / Media

PeriodOct 27 2015

Media coverage

36

Media coverage

  • TitleLeading U.S. Medical Association's Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletCNBC
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletReuters
    CountryUnited Kingdom
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association's Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletTMC Net
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletPharmiWeb
    CountryUnited Kingdom
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletIndustrial Info Financials
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletMarket Pulse Navigator
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletMoneyShow.com
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletMarketplace
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletPettinga Financial Advisors
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletWall Street Business Network
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletSearchBug
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletWall Street Select
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletTown Hall
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletCrawford Financial Planning
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletReliance Trust
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletRCL Advisors
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletFat Pitch Financials
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletEON: Enhanced Online News
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletSPi World News
    CountryUnited Kingdom
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletBioSpace
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletFinancial Content
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletCEOWorld Magazine
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletYahoo! Finance
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletFranklin Credit Management Corporation
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletYahoo! Finance UK and Ireland
    CountryUnited Kingdom
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletFreshnews.com
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletTamar Securities
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outlet4 Traders
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletGood Day Sacramento
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletConcord Monitor
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletStock Nod
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletBusiness Wire
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletAsk.com
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recomm
    Media name/outletU-T San Diego
    CountryUnited States
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Associations Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date10/27/15
    PersonsRalph A Defronzo
  • TitleLeading U.S. Medical Association’s Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date10/27/15
    PersonsRalph A Defronzo